Here are the Form 4 insider transactions from Ardelyx, Inc. (ARDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARDX filings page.
Ardelyx, Inc. reported an equity compensation grant to its Chief Human Resources Officer effective January 23, 2026. The officer received 99,455 restricted stock units (RSUs), with each RSU settling into one share of common stock upon vesting, increasing the officer’s directly held common stock to 265,455 shares. On the same date, the officer was also granted a stock option for 149,185 shares of common stock at an exercise price of $7.77 per share. The option vests in 48 equal monthly installments starting from January 23, 2026, conditioned on continued employment or service, and will remain exercisable until January 23, 2036.
Ardelyx Chief Patient Officer receives new equity awards. Laura A. Williams reported a grant of 82,695 shares of Ardelyx common stock on January 23, 2026, issued at $0 per share as restricted stock units that convert 1-for-1 into common stock when they vest. She also received a stock option for 124,040 shares of common stock at an exercise price of $7.77 per share, granted at no cost. The option vests in 48 equal monthly installments starting January 23, 2026, conditioned on her continued employment or service. Following these transactions, Williams directly beneficially owned 444,258 shares of Ardelyx common stock.
Ardelyx, Inc. reported an equity award to executive John E. Bishop, its Chief Technical and Quality Officer. On January 23, 2026, he received 124,330 shares of Common Stock in the form of restricted stock units, at a price of $0 per share, bringing his directly held Common Stock to 342,330 shares after the grant. He was also granted a stock option for 186,500 shares of Common Stock with an exercise price of $7.77 per share. The option vests in 48 equal monthly installments beginning on January 23, 2026, subject to his continued employment or service, and is exercisable through January 23, 2036.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an option exercise and share sale in Ardelyx common stock. On January 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $0.99 per share, then sold 50,000 shares at a weighted average price of $6.978 per share, with individual trades executed between $6.97 and $7.00.
After these transactions, Williams directly owned 361,563 shares of Ardelyx common stock, a figure that reflects an earlier purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. She also held 62,000 stock options with a $0.99 exercise price, expiring on January 6, 2032, which vest in equal monthly installments that began in January 2022.